AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT107.40-0.91 (-0.84%) ▼|ACN180.14-6.56 (-3.51%) ▼|ADBE259.44-7.07 (-2.65%) ▼|AMAT469.15+14.44 (+3.18%) ▲|AMD491.64+14.07 (+2.95%) ▲|AMGN403.23-34.00 (-7.78%) ▼|AMT175.47-0.28 (-0.16%) ▼|AMZN255.62-2.90 (-1.12%) ▼|AVGO366.80+8.91 (+2.49%) ▲|AXP322.83-3.26 (-1.00%) ▼|BA211.71-0.52 (-0.24%) ▼|BAC62.36-0.33 (-0.52%) ▼|BKNG187.95-5.34 (-2.76%) ▼|BLK1,107.63-8.47 (-0.76%) ▼|BMY64.75-2.09 (-3.12%) ▼|BNY163.27-1.58 (-0.96%) ▼|BRK-B501.63-4.27 (-0.84%) ▼|C136.21-1.53 (-1.11%) ▼|CAT820.33+6.47 (+0.80%) ▲|CL88.13-0.63 (-0.71%) ▼|CMCSA26.23-0.27 (-1.00%) ▼|COF216.53-3.02 (-1.38%) ▼|COP136.05+1.76 (+1.31%) ▲|COST911.37-4.38 (-0.48%) ▼|CRM251.78-7.52 (-2.90%) ▼|CSCO109.01-0.19 (-0.17%) ▼|CVS95.50-1.25 (-1.29%) ▼|CVX211.96+3.43 (+1.64%) ▲|DE687.04-6.64 (-0.96%) ▼|DHR205.38-2.24 (-1.08%) ▼|DIS104.81-0.48 (-0.46%) ▼|DUK120.54+0.32 (+0.26%) ▲|EMR152.72-0.08 (-0.05%) ▼|FDX320.49-1.88 (-0.58%) ▼|GD359.99+0.60 (+0.17%) ▲|GE335.79-1.24 (-0.37%) ▼|GEV947.49+5.57 (+0.59%) ▲|GILD146.58-4.42 (-2.92%) ▼|GM87.23-0.51 (-0.58%) ▼|GOOG332.40-2.92 (-0.87%) ▼|GOOGL335.77-2.69 (-0.79%) ▼|GS1,033.62-4.68 (-0.45%) ▼|HD320.32-0.68 (-0.21%) ▼|HON208.32-1.29 (-0.62%) ▼|IBM231.56-3.28 (-1.40%) ▼|INTC101.68+5.88 (+6.14%) ▲|INTU321.32-11.38 (-3.42%) ▼|ISRG358.51-8.19 (-2.23%) ▼|JNJ268.32-6.83 (-2.48%) ▼|JPM357.00-1.62 (-0.45%) ▼|KO88.24+0.17 (+0.19%) ▲|LIN472.33-5.25 (-1.10%) ▼|LLY1,116.00-32.74 (-2.85%) ▼|LMT536.40+11.24 (+2.14%) ▲|LOW204.33-0.24 (-0.12%) ▼|LRCX316.43+8.78 (+2.85%) ▲|MA570.32-8.85 (-1.53%) ▼|MCD255.15-0.57 (-0.22%) ▼|MDLZ61.37+0.09 (+0.15%) ▲|MDT92.35-1.81 (-1.92%) ▼|META617.88+1.11 (+0.18%) ▲|MMM168.03-0.48 (-0.28%) ▼|MO68.94+0.07 (+0.10%) ▲|MRK146.57-3.76 (-2.50%) ▼|MS217.40-0.31 (-0.14%) ▼|MSFT494.03-5.67 (-1.13%) ▼|MU1,016.88+0.29 (+0.03%) ▲|NEE83.64+0.22 (+0.26%) ▲|NFLX76.53-1.73 (-2.20%) ▼|NKE38.47+0.06 (+0.14%) ▲|NOW135.36-5.91 (-4.18%) ▼|NVDA232.54+2.18 (+0.95%) ▲|ORCL169.32+10.49 (+6.60%) ▲|PEP138.17+0.54 (+0.39%) ▲|PFE27.80-0.65 (-2.27%) ▼|PG145.43-1.02 (-0.70%) ▼|PLTR174.60+0.27 (+0.15%) ▲|PM185.36+2.85 (+1.56%) ▲|QCOM179.87+11.13 (+6.59%) ▲|RTX199.98-0.81 (-0.40%) ▼|SBUX103.69-0.79 (-0.75%) ▼|SCHW109.24-0.05 (-0.05%) ▼|SO88.49+0.37 (+0.42%) ▲|SPG208.40-0.92 (-0.44%) ▼|T25.73+0.06 (+0.23%) ▲|TMO606.80-6.95 (-1.13%) ▼|TMUS182.45+0.93 (+0.51%) ▲|TSLA361.55+7.47 (+2.11%) ▲|TXN259.58+1.14 (+0.44%) ▲|UBER73.67-2.11 (-2.78%) ▼|UNH394.29-2.81 (-0.71%) ▼|UNP288.87-0.75 (-0.26%) ▼|UPS101.61-0.68 (-0.66%) ▼|USB62.97-0.40 (-0.62%) ▼|V371.17-3.81 (-1.01%) ▼|VZ50.32+0.19 (+0.37%) ▲|WFC89.02-0.92 (-1.02%) ▼|WMT106.22-0.92 (-0.86%) ▼|XOM162.07+2.61 (+1.64%) ▲|AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT107.40-0.91 (-0.84%) ▼|ACN180.14-6.56 (-3.51%) ▼|ADBE259.44-7.07 (-2.65%) ▼|AMAT469.15+14.44 (+3.18%) ▲|AMD491.64+14.07 (+2.95%) ▲|AMGN403.23-34.00 (-7.78%) ▼|AMT175.47-0.28 (-0.16%) ▼|AMZN255.62-2.90 (-1.12%) ▼|AVGO366.80+8.91 (+2.49%) ▲|AXP322.83-3.26 (-1.00%) ▼|BA211.71-0.52 (-0.24%) ▼|BAC62.36-0.33 (-0.52%) ▼|BKNG187.95-5.34 (-2.76%) ▼|BLK1,107.63-8.47 (-0.76%) ▼|BMY64.75-2.09 (-3.12%) ▼|BNY163.27-1.58 (-0.96%) ▼|BRK-B501.63-4.27 (-0.84%) ▼|C136.21-1.53 (-1.11%) ▼|CAT820.33+6.47 (+0.80%) ▲|CL88.13-0.63 (-0.71%) ▼|CMCSA26.23-0.27 (-1.00%) ▼|COF216.53-3.02 (-1.38%) ▼|COP136.05+1.76 (+1.31%) ▲|COST911.37-4.38 (-0.48%) ▼|CRM251.78-7.52 (-2.90%) ▼|CSCO109.01-0.19 (-0.17%) ▼|CVS95.50-1.25 (-1.29%) ▼|CVX211.96+3.43 (+1.64%) ▲|DE687.04-6.64 (-0.96%) ▼|DHR205.38-2.24 (-1.08%) ▼|DIS104.81-0.48 (-0.46%) ▼|DUK120.54+0.32 (+0.26%) ▲|EMR152.72-0.08 (-0.05%) ▼|FDX320.49-1.88 (-0.58%) ▼|GD359.99+0.60 (+0.17%) ▲|GE335.79-1.24 (-0.37%) ▼|GEV947.49+5.57 (+0.59%) ▲|GILD146.58-4.42 (-2.92%) ▼|GM87.23-0.51 (-0.58%) ▼|GOOG332.40-2.92 (-0.87%) ▼|GOOGL335.77-2.69 (-0.79%) ▼|GS1,033.62-4.68 (-0.45%) ▼|HD320.32-0.68 (-0.21%) ▼|HON208.32-1.29 (-0.62%) ▼|IBM231.56-3.28 (-1.40%) ▼|INTC101.68+5.88 (+6.14%) ▲|INTU321.32-11.38 (-3.42%) ▼|ISRG358.51-8.19 (-2.23%) ▼|JNJ268.32-6.83 (-2.48%) ▼|JPM357.00-1.62 (-0.45%) ▼|KO88.24+0.17 (+0.19%) ▲|LIN472.33-5.25 (-1.10%) ▼|LLY1,116.00-32.74 (-2.85%) ▼|LMT536.40+11.24 (+2.14%) ▲|LOW204.33-0.24 (-0.12%) ▼|LRCX316.43+8.78 (+2.85%) ▲|MA570.32-8.85 (-1.53%) ▼|MCD255.15-0.57 (-0.22%) ▼|MDLZ61.37+0.09 (+0.15%) ▲|MDT92.35-1.81 (-1.92%) ▼|META617.88+1.11 (+0.18%) ▲|MMM168.03-0.48 (-0.28%) ▼|MO68.94+0.07 (+0.10%) ▲|MRK146.57-3.76 (-2.50%) ▼|MS217.40-0.31 (-0.14%) ▼|MSFT494.03-5.67 (-1.13%) ▼|MU1,016.88+0.29 (+0.03%) ▲|NEE83.64+0.22 (+0.26%) ▲|NFLX76.53-1.73 (-2.20%) ▼|NKE38.47+0.06 (+0.14%) ▲|NOW135.36-5.91 (-4.18%) ▼|NVDA232.54+2.18 (+0.95%) ▲|ORCL169.32+10.49 (+6.60%) ▲|PEP138.17+0.54 (+0.39%) ▲|PFE27.80-0.65 (-2.27%) ▼|PG145.43-1.02 (-0.70%) ▼|PLTR174.60+0.27 (+0.15%) ▲|PM185.36+2.85 (+1.56%) ▲|QCOM179.87+11.13 (+6.59%) ▲|RTX199.98-0.81 (-0.40%) ▼|SBUX103.69-0.79 (-0.75%) ▼|SCHW109.24-0.05 (-0.05%) ▼|SO88.49+0.37 (+0.42%) ▲|SPG208.40-0.92 (-0.44%) ▼|T25.73+0.06 (+0.23%) ▲|TMO606.80-6.95 (-1.13%) ▼|TMUS182.45+0.93 (+0.51%) ▲|TSLA361.55+7.47 (+2.11%) ▲|TXN259.58+1.14 (+0.44%) ▲|UBER73.67-2.11 (-2.78%) ▼|UNH394.29-2.81 (-0.71%) ▼|UNP288.87-0.75 (-0.26%) ▼|UPS101.61-0.68 (-0.66%) ▼|USB62.97-0.40 (-0.62%) ▼|V371.17-3.81 (-1.01%) ▼|VZ50.32+0.19 (+0.37%) ▲|WFC89.02-0.92 (-1.02%) ▼|WMT106.22-0.92 (-0.86%) ▼|XOM162.07+2.61 (+1.64%) ▲|
20 C
New York
Tuesday, September 8, 2026

Tag: congress

newssourceFORcompanyinformationcontent1releasesmarket

Yili Secures Four World Dairy Innovation Awards at the 18th Global Dairy Congress

AMSTERDAM, June 23, 2025 /PRNewswire/ -- On June 18–19, the Global Dairy Congress 2025 was held in Amsterdam. At the forum, Dr. Ignatius Szeto, Assistant President...

Yili Secures Four World Dairy Innovation Awards at the 18th Global Dairy Congress

AMSTERDAM, June 23, 2025 /PRNewswire/ -- On June 18–19, the Global Dairy Congress 2025 was held in Amsterdam. At the forum, Dr. Ignatius Szeto, Assistant President...

Yili Secures Four World Dairy Innovation Awards at the 18th Global Dairy Congress

AMSTERDAM, June 23, 2025 /CNW/ -- On June 18–19, the Global Dairy Congress 2025 was held in Amsterdam. At the forum, Dr. Ignatius Szeto, Assistant President...

Yili Secures Four World Dairy Innovation Awards at the 18th Global Dairy Congress

AMSTERDAM, June 23, 2025 /PRNewswire/ -- On June 18–19, the Global Dairy Congress 2025 was held in Amsterdam. At the forum, Dr. Ignatius Szeto, Assistant President...

IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy...

SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development,...

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are...

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are...

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /CNW/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are...

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are...

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data...

Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well-tolerated with no safety concerns in adults and adolescents living with haemophilia A, with or without inhibitors1. Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with an overall strong user preference for the pen-injector compared to the previous emicizumab injection system2,3. The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C.

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the...

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCongress

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers